1. Introduction {#sec0005}
===============

Stroke is the second-most cause of mortality and the third leading cause for disability, worldwide ([@ref034]; [@ref038]; [@ref046]; [@ref047]; [@ref052]). When strokes transpire, whether they are ischemic or hemorrhagic, the injured brain region correlates with its related loss of function which may be visual, motor, sensory or cognitive impairments. Most stroke studies focus on motor functions. However, it is estimated that nearly half of the survivors suffer from different degrees of cognitive dysfunction ([@ref030]; [@ref035]; [@ref078]).

The two leading subtypes of stroke are ischemic stroke, in 68% of the cases, and the less frequent hemorrhagic stroke, in 32% of the cases ([@ref008]; [@ref031]; [@ref052]; Zhang, Lo, Mychaskiw, & Colohan, 2005). Even though the two pathophysiological processes are diametrically opposed during the initiation phase, in the subacute chronic phase they culminate in comprised blood supply and subsequent brain ischemia ([@ref008]; [@ref031]; [@ref052]). When the insult results in cognitive dysfunction, usually more than one cognitive domain is involved such as memory, attention and visual spatial (VS) ([@ref002]; [@ref012]). The significant factors that affect the cognitive impairments' severity are older age, previous history of stroke, and the pre-injury global cognitive function (GCF) ([@ref003]; [@ref041]; [@ref050]; [@ref054]). It has been shown that hemorrhagic strokes cause significantly more cognitive impairments compared to ischemic strokes, and are more associated with cognitive deficits across multiple domains ([@ref012]). Cortical strokes were found with higher proportions of cognitive impairments in the memory domain than subcortical ones ([@ref033]; [@ref045]; [@ref059]). Yet, higher cortical functions such as expressive aphasia were significantly impaired in subcortical stroke patients as well as lower performances in the information processing speed (IPS) domain compared with cortical stroke patients ([@ref033]; [@ref045]; [@ref064]). With respect to dominant vs. non-dominant hemispheric lesion, there is evidence of a more severe cognitive impairments and an overall higher incidence of dementia following an insult in the dominant hemisphere ([@ref009]; [@ref013]; [@ref068]).

Reducing the impact of post-stroke cognitive impairment is an important goal due to the higher mortality and institutionalization rates of those patients ([@ref049]; [@ref069]). Rehabilitation includes a multidisciplinary approach which includes physiotherapy, speech and language therapy, cognitive rehabilitation therapy, medications and more. However, these programs have limited success ([@ref027]; [@ref053]; [@ref056]; [@ref074]). Cognitive recovery after stroke occurs mainly within the first 30 days, with some post-stroke patients continuing to gain progress up to three months from injury, yet even with domain specific interventions, improvement is minimal ([@ref034]; [@ref039]; [@ref048]).

Hyperbaric oxygen therapy (HBOT), the application of hyperbaric pressure in conjunction with increased oxygen content, has been shown in several clinical studies to have the capacity to induce neuroplasticity even years after an acute insult ([@ref004]; [@ref005]; [@ref016]; [@ref017]; [@ref018]; [@ref023]; [@ref024]; [@ref025], [@ref026]; [@ref065], [@ref066]; [@ref067]; [@ref076]). The elevated oxygen concentration in the blood and injured tissue during treatment ([@ref007]; [@ref044]; [@ref055]) helps supply the energy needed to regenerate damaged brain tissue. It has been shown that HBOT induced neuroplasticity is mediated by stimulating cell proliferation ([@ref042]), neurogenesis of endogenous neural stem cells ([@ref075]), regeneration of axonal white matter ([@ref010]), improved maturation and myelination of injured neural fibers ([@ref022]; [@ref073]), and stimulation of axonal growth, thus increasing the ability of neurons to function and communicate with each other ([@ref006]; [@ref043]). A retrospective analysis of post-stroke patients in the late chronic stage revealed that HBOT can significantly improve the memory domain ([@ref005]). However, the overall neurocognitive effects of HBOT and its relation to the different stroke types and anatomical locations were not investigated yet.

The aim of the current study is to investigate the effects of HBOT on the overall cognitive domains of post-stroke patients in the late chronic stage. The nature, type and location of the stroke as possible modifiers of HBOT effects were also investigated.

2. Methods {#sec0010}
==========

2.1. Participants {#sec0015}
-----------------

A retrospective study including post-stroke patients, more than three months post-injury, treated with HBOT between January 2008 and December 2017. The study was approved by our Institutional Review Board (approval number: 0206-17-ASF).

***Inclusion criteria:*** stroke more than three months prior to their first cognitive evaluation, completion of 40 or 60 hyperbaric oxygen sessions and at least two cognitive evaluations, 1--3 weeks prior to the first HBOT session to and 1--3 weeks after last HBOT session.

***Exclusion criteria:*** insufficient details of stroke nature, history of a potential additional brain injury (traumatic brain injury, anoxic brain injury, subarachnoid hemorrhage, etc.), lack of pre or post-HBOT cognitive evaluations.

2.2. Study design {#sec0020}
-----------------

The data were collected retrospectively from patients' medical records and included age, gender, level of education, handedness, stroke details (type, injured hemisphere, location of stroke, time from injury to HBOT, symptoms prior to treatment), number of HBOT sessions, chronic medical conditions (diabetes mellitus type II (DM II), hypertension (HTN), dyslipidemia, ischemic heart disease (IHD), previous stroke, smoking status), and chronic prescribed medications (anti-aggregation (AA)), statins, hypoglycemic medications, HTN medications). Data of the HBOT protocol, and adverse events were also collected.

The main analysis was to compare the stroke nature (hemorrhagic and ischemic) including all stroke locations: cortical, subcortical, atypical locations (i.e. cerebellum or brain stem) and multiple locations. A second analysis (i.e. the location analysis) compared the two main stroke locations, cortical and subcortical. To minimize unknown hemisphere dominance in left handed patients, a third analysis (i.e. the dominance analysis) included only the right-handed patients for evaluating the effect of the injured hemisphere.

2.3. Stroke subsets {#sec0025}
-------------------

Patients were divided into different groups based on their stroke prerequisites, retrieved from original imaging and medical records: by anatomical location: cortical (i.e. frontal, temporal, parietal and occipital cortex) or subcortical (i.e. basal ganglia (BG), cerebellum, pons, internal capsule and thalamus), by the injured hemisphere: right or left, and by stroke type: ischemic or hemorrhagic (See [Fig. 1](#rnn-38-rnn190959-g001){ref-type="fig"}).

![Flowchart of the patients included in the study.](rnn-38-rnn190959-g001){#rnn-38-rnn190959-g001}

2.4. Hyperbaric oxygen treatment {#sec0030}
--------------------------------

Participants were treated in a multi-place hyperbaric chamber (Haux-Life-Support GmbH, Germany) with the following protocols: 40 to 60 daily sessions, 5 days per week, each session included 90 min of 100% oxygen at 2 ATA with 5 min air breaks every 20 minutes.

2.5. Cognitive evaluation {#sec0035}
-------------------------

All the patients were inspected using the NeuroTrax computerized cognitive testing battery (NeuroTrax Corporation, Bellaire, TX). The NeuroTrax system and a detailed description of the tests included were detailed in previous publications([@ref001]; [@ref070]; [@ref081]) and are also available on the NeuroTrax website. In brief, NeuroTrax tests evaluate multiple aspects of brain cognitive functions including: memory, executive function (EF), visuospatial skills (VS), verbal function (VF), attention, information processing speed (IPS) and motor skills (MS). Cognitive domain scores were normalized for age, gender and education-specific levels.

The participants completed two validated alternate test forms of the NeuroTrax test battery at baseline and post-HBOT, to allow for iterative administrations with minimal learning effects. Test-retest reliability of the tests were found to be high in both normal and injured populations, without significant learning effects except in the VF & VS domains ([@ref015]; [@ref032]). Due to the low test-retest reliability of these domains, they were not evaluated in the current study.

2.6. Statistical analysis {#sec0040}
-------------------------

Data were expressed as mean±SD for parametric variables and frequencies, and percentages for nonparametric variables. Parametric variables were analyzed by paired-sample T tests for intra-group comparison and independent-sample t-tests for inter-group comparison, whereas nonparametric variables were analyzed by Pearson Chi-square test or Fisher's exact test (where suitable) to identify significant variables. Normal distribution for all continuous variables was tested using the Kolmogorov-Smirnov test.

Clinically significant improvement (CSI) was defined as an absolute increase of 7.5 points of the normalized score (0.5 of one standard deviation) in at least one cognitive domain. The cut-off for CSI was determined by previous studies ([@ref019]; [@ref060]).

Multiple linear regression models were performed to determine independent predictors for the post-treatment cognitive score. Multivariate logistic regression models were performed to control for potential confounders and to determine independent predictors for CSI. Models included the following covariates: age, sex, stroke type, location of stroke along with side of injured hemisphere, time from injury to HBOT, chronic medical conditions (DM II, HTN, dyslipidemia, IHD, active smoking), number of HBOT sessions and baseline score before HBOT treatment.

The alpha level was set to 0.05 (*p*-Value \< 0.05). The data were statistically analyzed using SPSS version 22 software.

3. Results {#sec0045}
==========

3.1. Participants' characteristics {#sec0050}
----------------------------------

Of the 351 patients who were assed for eligibility, a total of 162 met the inclusion criteria and were included in the final analysis ([Fig. 1](#rnn-38-rnn190959-g001){ref-type="fig"}). The patients' average age was 60.75±12.91 years old (23--83) and 122 (75.3%) were males. The average time from the stroke to HBOT was 2.78±3.3 years. Regarding the stroke type, 121 patients (74.69%) suffered from an ischemic stroke while 41 (25.31%) had a hemorrhagic stroke. In 50 patients (30.86%), the stroke was in the subcortical level, while 77 patients (47.53%) had a stroke in the cortical level and the remaining 35 patients (21.6%) were affected in atypical locations or multiple locations. With respect to the side of injury, 87 strokes (53.7%) were located in the right hemisphere, and 62 strokes (38.3%) were in the left hemisphere. Baseline participants characteristics are summarized in [Table 1](#rnn-38-rnn190959-t001){ref-type="table"}.

###### 

Patients' baseline characteristics

  Analysis                   Entire cohort (*n* = 162)     Location analysis (*n* = 127)   Dominance analysis (*n* = 110)  
  ------------------------ ------------------------------ ------------------------------- -------------------------------- --------------
  Age (years)                       60.75±12.91                     60.86±12.57                      61.23±12.3            
  Sex -- Males                      122 (75.3%)                     97 (76.4%)                       78 (70.9%)            
  Dominant hand -- Right            120 (74.1%)                      94 (74%)                        110 (100%)            
  Time from injury                    2.78±3.3                       2.53±2.95                       2.63±3.18             
  Num. of HBOT sessions             40 sessions                      26 (16%)                        22 (17.3%)              20 (18.2%)
                                    60 sessions                      136 (84%)                      105 (82.7%)              90 (81.8%)
  Type of stroke                      Ischemic                     121 (74.69%)                     98 (77.17%)              85 (77.3%)
                                    Hemorrhagic                     41 (25.31%)                      29 (22.8%)              25 (22.7%)
  Location of injury                Subcortical                     54 (33.3%)                       50 (39.4%)              36 (32.7%)
                                      Cortical                      80 (49.4%)                       77 (60.6%)              58 (52.7%)
                            Atypical &multiple locations             28 (17.3)                           --                 16 (14.5%)\*
  Side of injury                       Right                        62 (38.3%)                       53 (41.7%)              56 (50.9%)
                                        Left                        87 (53.7%)                       74 (58.3%)              54 (49.1%)
                                     Bilateral                        13 (8%)                            --                      --
  Symptoms                           Cognitive                      77 (47.5%)                       60 (47.2%)              49 (44.5%)
                                       Motor                        132 (81.5%)                     104 (81.9%)              90(81.8%)
                                       Speech                       65 (40.1%)                       54 (42.5%)              43 (39.1%)
                                         CN                         67 (41.4%)                       54 (42.5%)              46 (41.8%)
                                       Ataxia                       57 (35.2%)                       39 (30.7%)              34 (30.9%)
  Comorbidities                        DM II                        48 (29.6%)                       37 (29.1%)              28 (25.5%)
                                        HTN                          107 (66%)                       82 (64.6%)              74 (67.3%)
                                    Dyslipidemia                     107 (66%)                       82 (64.6%)              75 (68.2%)
                                        IHD                         39 (24.1%)                       30 (23.6%)              28 (25.5%)
                                  Previous stroke                   18 (11.1%)                       12 (9.4%)               10 (9.1%)
                                       Smoker                       29 (17.9%)                       23 (18.1%)              15 (13.6%)
  Medications                            AA                         105 (64.8%)                      78 (61.4%)              70 (63.6%)
                                      Statins                       104 (64.2%)                      79 (62.2%)              72 (65.5%)
                                 DM II medications                  37 (22.8%)                       27 (21.3%)              20 (18.2%)
                                  HTN medications                    107 (66%)                       84 (66.1%)              74 (67.3%)

Data are expressed as means±standard deviation. \*Cerebellum insult only. HBOT -- hyperbaric oxygen treatment, CN -- cranial nerves, DM II -- diabetic mellitus type 2, HTN -- hypertension, AA -- anti-aggregates.

3.2. Cognitive function changes {#sec0055}
-------------------------------

Basic analysis results revealed statistically significant improvements of all the cognitive domains after HBOT by 2.34-20 (*p* \< 0.05, see [Table 2](#rnn-38-rnn190959-t002){ref-type="table"}). The memory domain had the most prominent improvements of mean absolute change (MAC) (6.19±20, *p* = 0.0004, see [Table 2](#rnn-38-rnn190959-t002){ref-type="table"}). CSI was achieved in 86% of the patients in the entire cohort (see [Fig. 4](#rnn-38-rnn190959-g004){ref-type="fig"}). The effects of the HBOT on the cognitive scores is summarized in [Table 2](#rnn-38-rnn190959-t002){ref-type="table"}.

###### 

Cognitive domains -- mean absolute changes of the entire cohort

                       Pre score                  Post score                 Pre-Post MAC         *P*-value\*
  ----------- --------------------------- --------------------------- -------------------------- --------------
  GCF          **87.48** **±** **12.26**   **91.14** **±** **12.10**   **3.53** **±** **7.68**    **\<0.0001**
  Memory       **82.09** **±** **19.32**   **88.29** **±** **19.15**   **6.12** **±** **15.46**   **\<0.0001**
  EF           **88.61** **±** **14.15**   **91.09** **±** **12.65**   **2.54** **±** **10.37**    **0.003**
  Attention    **85.19** **±** **17.08**   **87.83** **±** **15.75**   **2.95** **±** **12.63**     **0.04**
  IPS          **83.54** **±** **15.45**   **86.34** **±** **17.07**   **2.34** **±** **9.28**     **0.005**
  MS           **91.91** **±** **17.13**   **95.21** **±** **15.89**   **3.96** **±** **14.27**    **0.001**

Data are expressed as means±standard deviation. \*Significant by two-tailed paired t-test. Bold text marks statistical significance (*P* \< 0.05). GCF -- global cognitive function, EF -- executive function, IPS -- information processing speed, MS -- motor skills.

### 3.2.1. Ischemic vs. hemorrhagic {#sec0060}

At baseline, there were significant differences in baseline characteristics between patients with ischemic compared to patients with hemorrhagic stroke which included age, presence of comorbidities, dyslipidemia and IHD, and medications prescribed (AA and statins) (*p* \< 0.05, see [Table 3](#rnn-38-rnn190959-t003){ref-type="table"}). In addition, the memory domain mean score of the ischemic stroke patients was significantly higher at baseline, compared to hemorrhagic stroke patients (83.87 vs 76.82, *p* = 0.043, [Table 4](#rnn-38-rnn190959-t004){ref-type="table"}).

###### 

Baseline characteristics comparison of patients with ischemic and hemorrhagic strokes

  Main analysis                 Ischemic (*n* = 121)       Hemorrhagic (*n* = 41)    *P*-value\*    
  ------------------------ ------------------------------ ------------------------ ---------------- --------------
  Age (years)                        62.78±12.3                 54.77±12.97           **0.001**     
  Sex -- males                       90 (74.4%)                   32 (78%)               0.64       
  Dominant hand -- right             91 (75.2%)                  29 (70.7%)             0.575       
  Time from injury                   2.82±3.52                   2.61±2.61               0.71       
  Location of injury                Subcortical                  38 (31.4%)            16 (39%)         0.138
                                      Cortical                   65 (53.7%)           15 (36.6%)    
                            Atypical &multiple locations         18 (14.9)            10 (24.4)     
  Side of injury                       Right                     66 (54.5%)           21 (51.2%)        0.524
                                        Left                     47 (38.8%)           15 (36.6%)    
                                     Bilateral                    8 (6.6%)            5 (12.2%)     
  Symptoms                           Cognitive                   53 (43.8%)           24 (58.5%)        0.104
                                       Motor                      98 (81%)            34 (82.9%)        0.784
                                       Speech                    45 (37.2%)           20 (48.8%)        0.193
                                         CN                       52 (43%)            15 (36.6%)        0.476
                                       Ataxia                    40 (33.1%)           17 (41.5%)        0.333
  Comorbidities                        DM II                     40 (33.1%)           8 (19.5%)         0.078
                                        HTN                      85 (70.2%)           22 (53.7%)        0.068
                                    Dyslipidemia               **90 (74.4%)**       **17 (41.5%)**   **\<0.0004**
                                        IHD                    **35 (28.9%)**        **4 (9.8%)**     **0.003**
                                  Previous stroke                15 (12.4%)            3 (7.3%)         0.374
                                       Smoker                    25 (20.7%)            4 (9.8%)         0.071
  Medications                            AA                     **92 (76%)**        **13 (31.7%)**   **\<0.0001**
                                      Statins                  **86 (71.1%)**       **18 (43.9%)**    **0.003**
                                 DM II medications               31 (25.6%)           6 (14.6%)         0.113
                                  HTN medications                85 (70.2%)           22 (53.7%)        0.068

Data are expressed as means±standard deviation. \*Significant by two-tailed paired t-test. Bold text marks statistical significance (*P* \< 0.05). CN -- cranial nerves, DM II -- diabetic mellitus type 2, HTN -- hypertension, AA -- anti-aggregates.

###### 

Pre-hyperbaric oxygen treatment cognitive domains scores

               Ischemic/hemorrhagic analysis       Location analysis       Dominance analysis                                                                                                  
  ----------- ------------------------------- --------------------------- -------------------- --------------------------- --------------------------- ----------- ------------- ------------- ---------
  GCF                   88.18±12.52                   85.42±11.36                0.214                 88.76±11.26                 84.95±13.53             0.1      88.81±11.77   87.8±14.28    0\. 686
  Memory         **83.87** **±** **18.45**     **76.82** **±** **21.06**       **0.043**               81.68±18.4                  80.72±20.18            0.788     87.15±18. 9   81.96±18.94    0.153
  EF                    88.6±14.26                    88.63±13.98                0.992          **92.37** **±** **13.61**   **85.19** **±** **15.11**   **0.009**   89.68±14.69   90.29±15.14    0.834
  Attention             85.65±17.54                   83.8±15.73                  0.56          **88.44** **±** **14.02**   **80.8** **±** **19.57**    **0.012**   84.93±17.57   86.33±18.33    0.685
  IPS                   84.68±15.7                    79.66±14.09                0.106                 83.55±14.22                 82.7±16.61             0.28      85.24±16.99   81.21±14.07     0.2
  MS                    91.56±17.79                   92.93±15.15                0.667                 92.79±16.25                 89.69±19.58            0.362     91.9±15.48    90.18±18.59    0.608

Data are expressed as means±standard deviation. \*Significant by two-tailed paired t-test. Bold text marks statistical significance (*P* \< 0.05). GCF -- global cognitive function, EF -- executive function, VS -- visual spatial, IPS -- information processing speed, MS -- motor skills.

Post-HBOT, the IPS domain had a significantly higher MAC in the hemorrhagic stroke patients compared to the ischemic stroke patients (5.39 vs. 1.36, *p* = 0.035, see [Fig. 2](#rnn-38-rnn190959-g002){ref-type="fig"}). There were no other significant differences in the surplus of the cognitive domains (*p* \> 0.05, see [Fig. 2](#rnn-38-rnn190959-g002){ref-type="fig"}). In addition, there were no significant changes in the CSI between hemorrhagic stroke patients compared to ischemic stroke patients (94.6% vs. 83.33%, *p* \> 0.05, see [Fig. 4](#rnn-38-rnn190959-g004){ref-type="fig"}).

![Hemorrhagic/ischemic stroke MAC comparison of cognitive scores post-HBOT. Only the IPS domain was significantly increased after HBOT for the hemorrhagic stroke patients compared to ischemic strokes. Statistical significance (*p* \< 0.05) is marked by \*. Bars represent means+standard deviation. Abbreviations: MAC -- mean absolute change, HBOT -- hyperbaric oxygen treatment, GCS -- global cognitive scale, EF -- executive function, IPS -- information processing speed, MS -- motor skills.](rnn-38-rnn190959-g002){#rnn-38-rnn190959-g002}

### 3.2.2. Cortical vs. subcortical {#sec0065}

At baseline, there were significant differences in speech symptoms and presence of HTN between patients with subcortical strokes compared to cortical stroke (*p* \< 0.05, see [Table 5](#rnn-38-rnn190959-t005){ref-type="table"}).

###### 

Baseline characteristics comparison of patients with cortical and subcortical strokes

  Location analysis         Subcortical (*n* = 50)   Cortical (*n* = 77)    *P*-value\*    
  ------------------------ ------------------------ --------------------- ---------------- -----------
  Age (years)                    62.31±11.28             59.91±13.32           0.296       
  Sex -- males                     42 (84%)              55 (71.4%)            0.091       
  Dominant hand -- right           36 (72%)              58 (75.3%)            0.679       
  Time from injury                2.58±2.87                2.51±3              0.895       
  Type of stroke                   Ischemic               35 (70%)           63 (81.8%)       0.121
                                 Hemorrhagic              15 (30%)           14 (18.2%)    
  Side of injury                    Right                 22 (44%)           31 (40.3%)       0.676
                                     Left                 28 (56%)           46 (59.7%)    
  Symptoms                        Cognitive               23 (46%)           37 (48.1%)       0.823
                                    Motor                 43 (86%)           61 (79.2%)       0.321
                                    Speech              **15 (30%)**       **39 (50.6%)**   **0.019**
                                      CN                  20 (40%)           34 (44.2%)       0.647
                                    Ataxia                20 (40%)           19 (24.7%)       0.077
  Comorbidities                     DM II                 19 (38%)           18 (23.4%)       0.087
                                     HTN                **38 (76%)**       **44 (57.1%)**   **0.026**
                                 Dyslipidemia             34 (68%)           48 (62.3%)       0.518
                                     IHD                  10 (20%)            20 (26%)        0.443
                               Previous stroke             7 (14%)            5 (6.5%)        0.192
                                    Smoker                 9 (18%)           14 (18.2%)       0.979
  Medications                         AA                  27 (54%)           51 (66.2%)       0.175
                                   Statins                31 (62%)           48 (62.3%)       0.97
                              DM II medications           13 (26%)           14 (18.2%)       0.311
                               HTN medications            36 (72%)           48 (62.3%)       0.097

Data are expressed as means±standard deviation. \*Significant by two-tailed paired t-test. Bold text marks statistical significance (*P* \< 0.05). CN -- cranial nerves, DM II -- diabetic mellitus type 2, HTN -- hypertension, AA -- anti-aggregates.

Compared to cortically located strokes, the EF & attention domains at baseline were significantly higher in the subcortically located strokes (92.37 vs. 85.19, *p* = 0.009, 88.44 vs. 80.78, *p* = 0.012, respectively, see [Table 4](#rnn-38-rnn190959-t004){ref-type="table"}). There were no other significant differences in cognitive domains (*p* \> 0.05, see [Table 4](#rnn-38-rnn190959-t004){ref-type="table"}).

Post-HBOT, there were no significant differences between patients with subcortical strokes compared to cortical strokes (*p* \> 0.05, see Supplementary Fig. I). Moreover, there were no significant changes in the CSI between subcortical strokes compared to cortical strokes (90% vs. 87.23%, *p* \> 0.05, see [Fig. 4](#rnn-38-rnn190959-g004){ref-type="fig"}).

### 3.2.3. Dominant vs. non-dominant hemisphere {#sec0070}

Including only right-handed patients, at baseline, there were significant differences in speech and motor symptoms between patients with left dominant hemisphere strokes compared to right non-dominant hemisphere strokes (*p* \< 0.05, see [Table 6](#rnn-38-rnn190959-t006){ref-type="table"}). There were no significant differences at baseline cognitive function between the dominant and non-dominant hemisphere strokes (*p* \> 0.05, see [Table 4](#rnn-38-rnn190959-t004){ref-type="table"}).

###### 

Baseline characteristics comparison of patients with dominant and non-dominant strokes

  Rt. handed analysis    Non-dominant (*n* = 56)   Dominant (*n* = 54)    *P*-value\*    
  --------------------- ------------------------- --------------------- ---------------- ------------
  Age (years)                  60.73±13.78             61.75±10.65           0.668       
  Sex -- males                 38 (67.9%)              40 (74.1%)           0\. 477      
  Time from injury              2.57±2.59               2.7±3.72             0.827       
  Type of stroke                Ischemic               44 (78.6%)          41 (75.9%)       0.741
                               Hemorrhagic             12 (21.4%)          13(24.1%)     
  Location of injury           Subcortical             20 (35.7%)          16 (29.6%)        0.72
                                Cortical               29 (51.8%)          29 (53.7%)    
                           Atypical Locations           7 (12.5%)          9 (16.7%)     
  Symptoms                      Cognitive              21 (37.5%)          28 (51.9%)       0.132
                                  Motor              **50 (89.3%)**      **40 (74.1%)**    **0.04**
                                 Speech              **13 (23.2%)**      **30 (55.6%)**   **0.0004**
                                   CN                  20 (35.7%)          26 (48.1%)        0.19
                                 Ataxia                17 (30.4%)          17 (31.5%)        0.9
  Comorbidities                   DM II                 14 (25%)           14 (25.9%)       0.912
                                   HTN                 37 (66.1%)          37 (68.5%)       0.787
                              Dyslipidemia             37 (66.1%)          38 (70.4%)       0.632
                                   IHD                 13 (23.2%)          15 (27.8%)       0.587
                             Previous stroke          **2 (3.6%)**       **8 (14.8%)**    **0.044**
                                 Smoker                10 (17.9%)           5 (9.3%)         0.19
  Medications                      AA                  35 (62.5%)          35 (64.8%)       0.803
                                 Statins               35 (62.5%)          37 (68.5%)       0.511
                            DM II medications          12 (22.2%)          8 (14.3%)        0.286
                             HTN medications           34 (60.7%)          40 (74.1%)       0.137

Data are expressed as means±standard deviation. \*Significant by two-tailed paired *t*-test. Bold text marks statistical significance (*P* \< 0.05). CN -- cranial nerves, DM II -- diabetic mellitus type 2, HTN -- hypertension, AA -- anti-aggregates.

Post-HBOT, there were significantly larger increases in MAC in the motor domains for patients with left hemisphere strokes compared to right hemisphere strokes (8.02 vs. 1.42, *p* = 0.023, see [Fig. 3](#rnn-38-rnn190959-g003){ref-type="fig"}). There were no other significant differences for the surplus cognitive domains (*p* \> 0.05, see [Fig. 3](#rnn-38-rnn190959-g003){ref-type="fig"}).

![Dominant/non-dominant MAC comparison of cognitive scores post-HBOT. The motor domain was significantly increased after HBOT at the dominant (i.e. left sided) stroke patients compared to non-dominant strokes. Statistical significance (*p* \< 0.05) is marked by \*. Bars represent means+standard deviation. Abbreviations: MAC -- mean absolute change, HBOT -- hyperbaric oxygen treatment, GCS -- global cognitive scale, EF -- executive function, IPS -- information processing speed, MS -- motor skills.](rnn-38-rnn190959-g003){#rnn-38-rnn190959-g003}

There were no significant changes in the CSI between left dominant hemisphere strokes compared to right non-dominant hemisphere stroke patients (90.57% vs. 76.47%, *p* \> 0.05, see [Fig. 4](#rnn-38-rnn190959-g004){ref-type="fig"}).

![Clinically significant improvement comparisons of hemorrhagic vs. ischemic, cortical vs. sub-cortical and dominant vs. non-dominant stroke patients. Scores were not significantly different in all the domains (*p* \> 0.05). Bars represent percentages.](rnn-38-rnn190959-g004){#rnn-38-rnn190959-g004}

![Cortical/subcortical (i.e. BG) MAC comparison of cognitive scores post HBOT. Scores MAC were not significantly different in all the domains (*p* \> 0.05). Bars represent means+standard deviation. Abbreviations: MAC -- mean absolute change, HBOT -- hyperbaric oxygen treatment, GCS -- global cognitive scale, EF -- executive function, IPS -- information processing speed, MS -- motor skills.](rnn-38-rnn190959-g005){#rnn-38-rnn190959-g005}

3.3. Cognitive scores outcome predictors {#sec0075}
----------------------------------------

Forward stepwise multivariate linear regression models were performed on the entire cohort as well as on the location and dominance cohorts. The only major statistically significant predictor on the post-HBOT score in all of the domains and analyses was the baseline cognitive domain score. Age, gender, handedness, stroke details (type, injured hemisphere, location, time from injury to HBOT), number of HBOT sessions, chronic medical conditions (DM II, HTN, dyslipidemia, IHD, previous stroke), smoking status, chronic prescribed medications (AA, statins, DM II medications, HTN medications) had no effect in most domains.

HTN was a significant predictor on post-HBOT score in the GCS for the dominance analysis only, and the number of HBOT sessions was a significant predictor on post-HBOT in the EF domain for all analyses.

Forward stepwise multivariate logistic regression models were performed on the three different analyses, to evaluate significant predictors for CSI percentage. Low baseline cognitive memory domain score was the only statistically significant predictor on the CSI prevalence in the main and location analyses (OR = 0.94 (\[0.909-- 0.972\], *p* \< 0.0003), OR = 0.948 (\[0.912-- 0.985\], *p* = 0.007), respectively). In the dominance analysis, the low baseline cognitive memory domain score and shorter times that passed since the event to HBOT were the statistically significant predictors on the post-HBOT score (OR = 0.949 (\[0.912-- 0.986\], *p* = 0.008), OR = 0.82 (\[0.692-- 0.972\], *p* = 0.022), respectively).

3.4. Safety {#sec0080}
-----------

There were twelve (7.4%) side effect reports in the entire cohort. Eight experienced barotrauma (8/162, 4.93%). Barotraumas were mild and all patients fully recovered after a few days. In addition, three patients (1.85%) reported minor otalgia without objective barotrauma. One patient (0.06%) reported a mild headache during recompression. In addition, two patients with histories of known seizures prior to HBOT suffered seizures after a few sessions of HBOT. The seizures did not occur while in the hyperbaric chamber and once the patients reported about them, their anti-epileptic drugs were modified, and they resumed HBOT shortly.

4. Discussion {#sec0085}
=============

In the current study, the effect of HBOT on post-stroke patients in the late chronic stages was analyzed. Even though the patients were treated after a median of 1.5±3.3 years post-stroke, there were significant cognitive improvements in all the cognitive domains which were measured using objective computerized tests. Moreover, clinical significant improvements (CSI) were achieved in 86% of patients, with the most significant measurable improvements gained in the dominant hemisphere stroke patients. Low baseline memory score was the significant predictor for CSI. Hemorrhagic stroke patients had significantly higher improvement in IPS, but no other differences were found compared to ischemic strokes. There were no significant differences in HBOT effects on subcortical compared to cortical strokes. Patients with strokes located in the dominant hemisphere had significantly larger improvement in the MS domain.

In the current study, there were significant improvements in all the cognitive domains which reconfirms previous studies that evaluated the therapeutic effect of HBOT in the chronic late stage of post-stroke patients ([@ref005]; [@ref025]; [@ref057]; [@ref072]). In a previous study, there were significant improvements in the neurological functions, tested by the National Institutes of Health stroke scale (NIHSS), activities of daily living (ADL) and quality of life ([@ref017]). However, cognitive domains were not reported. A later retrospective study reported significant improvements in the memory domain after HBOT. Yet, the other cognitive domains were not explored and the stroke nature was not evaluated as a possible confounder ([@ref005]). Churchill published a prospective study ([@ref011]) that included 22 patients at least one year after stroke. HBOT induced improvement in symptoms reports (51% memory, 51% attention/concentration, 48% balance/coordination, 45% endurance, 20% sleep). However, on standardized evaluations of cognition and questionnaires no significant changes were reported. Another small prospective study on seven patients showed verbal memory and executive function improvements in addition to sleep and quality of life changes ([@ref057]).

The differences between hemorrhagic and ischemic strokes were mild but evident in the high cognitive function domain (i.e. the IPS) which correlates with the usually more severe outcomes of post-hemorrhagic stroke patients and the cognitive deficits across multiple domains ([@ref012]). This domain is more sensitive than the other cognitive domains to an insult due to its integrating role on other domains and its influence on downstream processes, which is manifested in the domains score. Nevertheless, hemorrhagic stroke patients showed significant improvements post-HBOT and the low baseline cognitive domain score remained the major predictor for the post-HBOT domain score.

The lack of any significant differences after HBOT between cortical and subcortical strokes is surprising. Similar to our study, previous studies showed subcortical stroke patients have higher post-stroke cognitive scores compared to cortical stroke patients ([@ref020]; [@ref029]). However, post-- HBOT, there were no significant differences between the two types. Even though it is expected that subcortical strokes will have lower proportions of memory impairments (and conversely for the IPS domain), no such differences were seen after HBOT treatment. Our results indicate that the excess oxygen from HBOT treatments functions on all ischemic areas regardless of their anatomical area. As expected, the higher improvements in the MS domain seen in the dominant stroke patients, lies in the basic functionality of the dominant side.

The lack of any significant difference regarding HBOT's beneficial effects to the stroke's origin and location could be explained by the common pathophysiological final path of injury, i.e. ischemic/metabolic dysfunctional cells in injured non necrotic brain regions. As seen in previous studies, stroke patients may have chronic penumbra even years after the insult, which can be identified using SPECT imaging ([@ref011]; [@ref028]). Oxygenation improves energy metabolism in the border zones of focal cerebral ischemia represented by significant reduction of areas with tissue acidosis and areas with ATP depletion ([@ref062]; [@ref063]).HBOT can also decrease the post ischemic inflammatory response by reducing blood-brain-barrier damage ([@ref071]), inflammatory cytokines release ([@ref079]) and suppresses the aggravated response of astrocytes and microgliosis ([@ref021]). Recently, it was shown HBOT mitigates the inflammatory response of the neuronal cells through the transfer of mitochondria from astrocytes ([@ref036]). HBOT reduces apoptosis which enables to preserve more brain tissues and promote neurologic functional recovery ([@ref077]). Opening of mitochondrial ATP-sensitive potassium channel plays a role in this antiapoptotic effect of early hyperbaric oxygenation ([@ref037]). The intermittent hyperoxic exposure during HBOT can induce hypoxia inducible factor-1 alpha (HIF-1*α*) by the so called "Hyperoxic-Hypoxic paradox"([@ref014]; [@ref049]; [@ref051]; [@ref061]). HIF-1*α* is transcriptional regulator of genes involved in angiogenesis, energy metabolism, and neuronal cell proliferation induced by HBOT ([@ref014]; [@ref049]; [@ref051]; [@ref061]).

In summary, HBOT induces neuroplasticity, by two main physiological effects: increasing tissue oxygenation -- the rate limiting factor for all regenerative mechanisms, and the repeated oxygen level fluctuations which increases HIF-1*α* which in turn triggers the regenerative processes in the metabolically injured brain areas regardless of the stroke origin ([@ref016]; [@ref017]). Therefore, the selection of stroke patients for HBOT should be based on functional imaging and baseline cognitive domain scores rather than stroke type, location or side of lesion.

The current study presents the largest cohort of post-stroke patients treated with HBOT in the late chronic stage. However, it has several limitations, which are mostly related to the fact that data were collected retrospectively. Still, the findings presented here are in agreement with previous prospective RCT's in which the neuroplasticity effects of HBOT were established \[28, 37, 48\]. These therapeutic effects were seen in our study in the chronic stage when patients are not expected to improve. Another study limitation is the missing data on the treatment's long-term effects. Further long-term prospective studies should be performed.

Another important limitation relates to the HBOT protocol which was inconsistent in the cohort, where several patients received 40 sessions compared to 60 sessions in most patients. Although significant neurotherapeutic effects were shown with both these protocols, the optimal protocol, which induces maximal neuroplasticity with minimal side effects, remains unknown.

5. Conclusions {#sec0090}
==============

HBOT was found, in the largest post-stroke population published, to induce significant improvements in all cognitive function domains even at the late chronic stage. Patients selection for HBOT should be based on functional imaging and baseline cognitive function, regardless of stroke type and location. Further studies are needed to validate these findings for the optimal patient selection.
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